IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12239655 B1

PDFFull Text
Date of Patent:
Mar. 04, 2025

Filed:

Dec. 27, 2018

Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents

Applicants:

Raymond F. Schinazi, Atlanta, GA (US);

Franck Amblard, Atlanta, GA (US);

Christina Gavegnano, Atlanta, GA (US);

Bryan Cox, Atlanta, GA (US);

Seema Mengshetti, Atlanta, GA (US);

Inventors:

Raymond F. Schinazi, Atlanta, GA (US);

Franck Amblard, Atlanta, GA (US);

Christina Gavegnano, Atlanta, GA (US);

Bryan Cox, Atlanta, GA (US);

Seema Mengshetti, Atlanta, GA (US);

Assignee:

Emory University, Atlanta, GA (US);

Attorneys:

David S. Bradin

Maynard Nexsen PC

Primary Examiner:

Layla D Berry

Int. Cl.
CPC ...
A61K 31/7076 (2006.01); A61K 31/12 (2006.01); A61K 31/17 (2006.01); A61K 31/41 (2006.01); A61K 31/428 (2006.01); A61K 31/437 (2006.01); A61K 31/45 (2006.01); A61K 31/519 (2006.01); A61K 31/5415 (2006.01); A61K 31/69 (2006.01); A61K 31/7072 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); A61P 31/16 (2006.01); A61P 31/18 (2006.01); A61P 31/22 (2006.01); C07C 275/40 (2006.01); C07D 275/04 (2006.01); C07D 279/20 (2006.01); C07D 417/04 (2006.01); C07D 471/04 (2006.01); C07H 19/10 (2006.01); C07H 19/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7076 (2013.01); A61K 31/12 (2013.01); A61K 31/17 (2013.01); A61K 31/41 (2013.01); A61K 31/428 (2013.01); A61K 31/437 (2013.01); A61K 31/45 (2013.01); A61K 31/519 (2013.01); A61K 31/5415 (2013.01); A61K 31/69 (2013.01); A61K 31/7072 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); A61P 31/16 (2018.01); A61P 31/18 (2018.01); A61P 31/22 (2018.01); C07C 275/40 (2013.01); C07D 275/04 (2013.01); C07D 279/20 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07H 19/10 (2013.01); C07H 19/16 (2013.01);
Abstract

Nucleoside compounds, which in some embodiments include an alkynyl substituent at the 4'-position, compositions and methods for treating or preventing HIV and other viral infections, particularly where the virus is present in macrophages, microglia, and primary myeloid cells, and eliminating and/or treating infection in patients infected by these viruses, are disclosed.

Find Patent Forward Citations

Loading…